Summary
Objective Ultra long-term subcutaneous EEG (sqEEG) monitoring is a new modality with great potential for both health and disease, including epileptic seizure detection and forecasting. However, little is known about the long-term quality and consistency of the sqEEG signal, which is the objective of this study.
Methods The largest multicenter cohort of sqEEG was analyzed, including fourteen patients with epilepsy and twelve healthy subjects, implanted with a sqEEG device (24/7 EEG™ SubQ), and recorded from 23 to 230 days (median 42 days), with a median data capture rate of 75% (17.9 hours/day). Median power spectral density plots of each subject were examined for physiological peaks, including at diurnal and nocturnal periods. Long-term temporal trends in signal impedance and power spectral features were investigated with subject-specific linear regression models and group-level linear mixed effects models.
Results sqEEG spectrograms showed an approximately 1/f power distribution. Diurnal peaks in the alpha range (8-13Hz) and nocturnal peaks in the sigma range (12-16Hz) were seen in the majority of subjects. Signal impedances remained low and frequency band powers were highly stable throughout the recording periods.
Significance The spectral characteristics of minimally-invasive, ultra long-term sqEEG are similar to scalp EEG, while the signal is highly stationary. Our findings reinforce the suitability of this system for chronic implantation on diverse clinical applications, from seizure detection and forecasting to brain-computer interfaces.
Key Points
Subcutaneous EEG shows similar spectral characteristics to scalp EEG
The subcutaneous EEG signal is highly stable throughout weeks and months of recording
Subcutaneous EEG systems are well suited for chronic implantation, for seizure detection and seizure forecasting
Competing Interest Statement
JDH and LSR are employees of UNEEG medical A/S. ESN and DF are employees and shareholders of Seer Medical. BHB has equity in Cadence Neurosciences and has received research devices from Medtronic Inc. at no cost. MPR has been a member of ad-hoc advisory boards for UNEEG medical A/S. PFV received a payment from UNEEG medical A/S for data annotation in an unrelated research study. No other authors have conflicts to declare.
Clinical Trial
NCT04061707
Funding Statement
This work was supported by the Epilepsy Foundation Epilepsy Innovation Institute My Seizure Gauge Project. MPR is supported by the NIHR Biomedical Research Centre; the MRC Centre for Neurodevelopmental Disorders (MR/ N026063/1); the RADAR-CNS project funded by the European Commission (www.radar-cns.org, grant agreement 115902).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
London-Bromley REC (19/LO/0354) Committee of science ethics for Region Zealand (SJ‐551)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data is currently unavailable; is planned to become available at a future date.
